课题基金 / 基金详情

AAOHNS--CLINICAL TRIALS COOPERATIVE GROUP

AAOHNS--CLINICAL TRIALS COOPERATIVE GROUP
AAOHNS--临床试验合作组织
批准号:
2900057
负责人:
Patrick E Brookhouser
金额:
$117.48万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-04-15 至 2002-03-31

项目摘要

项目成果

Patrick E Brookhouser的其他基金

相似基金

相关文献

中文摘要
翻译
本申请寻求临床试验合作小组的支持
英文摘要
This application seeks support for a Clinical Trials Cooperative Group dedicated to the planning, conduct, analysis, and dissemination of results of clinical studies on the treatment or management of diseases and disorders of hearing, balance, smell, taste, speech, and voice or any combination. The Group structure includes: A Central Office (CO); a Central Trials Coordination Unit (TCU) experienced in the data management and statistical aspects of clinical trials; and a network of participating Investigator Groups (IG). This application proposes the American Academy of Otolaryngology-Head and Neck Surgery Foundation, Inc. (AAO-HNSF) as the CO; a group of senior investigators at the Bowman Gray School of Medicine Dept. of Public Health Sciences as the central TCU, and a group of highly experienced, research-oriented otolaryngologists representing over 20 major public and private university medical centers in the United States as the IG. The Otolaryngology Clinical Trials Cooperative Group (OCTCG) will have overarching responsibilities related to the development of clinical trials, selection of participating units, setting standards for conduct, quality control, and publications for individual clinical trials and for enhancing the disseminatIon of results from OCTCG clinical trials. The first trial proposed will investigate treatment of autoimmune inner ear disease, a potentially devastating condition that, left untreated, can lead to total deafness and disequilibrium in a very short time period. Available treatments for this condition (high dose prednisone methotrexate, cyclophosphamide) are currently utilized without proof of efficacy or assessment of risks. Using a multi institutional, prospective, double blind, placebo controlled design, the study will address the important clinical question of whether it is an acceptable risk to treat AIED with potent and potentially toxic immunosuppressive drugs when corticosteroids fail to control the disease. The dissemination of these results through the OCTCG should allow the timely transfer of information directly to clinical practice.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
AAOHNS--CLINICAL TRIALS COOPERATIVE GROUP
AAOHNS--CLINICAL TRIALS COOPERATIVE GROUP
AAOHNS--CLINICAL TRIALS COOPERATIVE GROUP
AAOHNS--CLINICAL TRIALS COOPERATIVE GROUP
海外基金